IN2008CN05409A - - Google Patents

Download PDF

Info

Publication number
IN2008CN05409A
IN2008CN05409A IN5409CHN2008A IN2008CN05409A IN 2008CN05409 A IN2008CN05409 A IN 2008CN05409A IN 5409CHN2008 A IN5409CHN2008 A IN 5409CHN2008A IN 2008CN05409 A IN2008CN05409 A IN 2008CN05409A
Authority
IN
India
Prior art keywords
compositions
conjugates
drugs
useful
addiction
Prior art date
Application number
Other languages
English (en)
Inventor
Martin F Bachmann
Patrik Maurer
Original Assignee
Cytos Biotechnology Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytos Biotechnology Ag filed Critical Cytos Biotechnology Ag
Publication of IN2008CN05409A publication Critical patent/IN2008CN05409A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0013—Therapeutic immunisation against small organic molecules, e.g. cocaine, nicotine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/18011—Details ssRNA Bacteriophages positive-sense
    • C12N2795/18111—Leviviridae
    • C12N2795/18123—Virus like particles [VLP]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Addiction (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IN5409CHN2008 2002-07-18 2003-07-18 IN2008CN05409A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39657502P 2002-07-18 2002-07-18
PCT/EP2003/007850 WO2004009116A2 (fr) 2002-07-18 2003-07-18 Conjugues haptene-porteur et utilisations de ceux-ci

Publications (1)

Publication Number Publication Date
IN2008CN05409A true IN2008CN05409A (fr) 2015-10-02

Family

ID=30770921

Family Applications (1)

Application Number Title Priority Date Filing Date
IN5409CHN2008 IN2008CN05409A (fr) 2002-07-18 2003-07-18

Country Status (16)

Country Link
US (4) US6932971B2 (fr)
EP (2) EP1523334A2 (fr)
JP (1) JP5084103B2 (fr)
KR (2) KR101228376B1 (fr)
CN (2) CN101574518B (fr)
AU (1) AU2003250106B2 (fr)
BR (1) BR0312297A (fr)
CA (1) CA2487849A1 (fr)
IL (1) IL165249A0 (fr)
IN (1) IN2008CN05409A (fr)
MX (1) MXPA04012010A (fr)
NZ (1) NZ537003A (fr)
PL (1) PL375598A1 (fr)
RU (2) RU2326693C2 (fr)
WO (1) WO2004009116A2 (fr)
ZA (1) ZA200409389B (fr)

Families Citing this family (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020032316A1 (en) * 1995-03-31 2002-03-14 Cantab Pharmaceuticals Research Limited Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
WO2001085208A2 (fr) * 2000-05-05 2001-11-15 Cytos Biotechnology Ag Jeu ordonne d'antigenes moleculaires
US7094409B2 (en) 2001-01-19 2006-08-22 Cytos Biotechnology Ag Antigen arrays for treatment of allergic eosinophilic diseases
US7320793B2 (en) * 2001-01-19 2008-01-22 Cytos Biotechnology Ag Molecular antigen array
US7128911B2 (en) 2001-01-19 2006-10-31 Cytos Biotechnology Ag Antigen arrays for treatment of bone disease
SE521512C2 (sv) * 2001-06-25 2003-11-11 Niconovum Ab Anordning för administrering av en substans till främre delen av en individs munhåla
US7115266B2 (en) 2001-10-05 2006-10-03 Cytos Biotechnology Ag Angiotensin peptide-carrier conjugates and uses thereof
BR0311995A (pt) * 2002-06-20 2005-04-05 Cytos Biotechnology Ag Partìculas semelhantes a vìrus empacotadas para o uso como adjuvantes: método de preparação e uso
JP4726483B2 (ja) * 2002-07-17 2011-07-20 サイトス バイオテクノロジー アーゲー 分子抗原アレイ
KR101228376B1 (ko) * 2002-07-18 2013-01-31 사이토스 바이오테크놀로지 아게 합텐-캐리어 컨쥬게이트 및 그의 용도
DE60336902D1 (de) * 2002-07-19 2011-06-09 Cytos Biotechnology Ag Impfstoffzusammensetzungen enthaltende amyloid beta 1-6 antigenarrays
DK1803443T3 (en) * 2002-12-20 2019-02-25 Niconovum Ab Nicotine-containing particulate material with a crystalline cellulose
WO2005030798A2 (fr) * 2003-09-24 2005-04-07 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Agents inhibiteurs et agents stimulateurs de l'enzyme de conversion du tnf-$g(a)
US7923109B2 (en) 2004-01-05 2011-04-12 Board Of Regents, The University Of Texas System Inorganic nanowires
GB0419199D0 (en) * 2004-08-27 2004-09-29 Curidium Ltd Methods of diagnosis
CN101052411B (zh) * 2004-10-05 2011-04-06 赛托斯生物技术公司 Vlp-抗原偶联物及其作为疫苗的用途
AU2005298689A1 (en) 2004-10-25 2006-05-04 Cytos Biotechnology Ag Gastric inhibitory polypeptide (GIP) antigen arrays and uses thereof
US9492400B2 (en) 2004-11-04 2016-11-15 Massachusetts Institute Of Technology Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
GB0424563D0 (en) 2004-11-05 2004-12-08 Novartis Ag Organic compounds
US20060111271A1 (en) * 2004-11-24 2006-05-25 Cerny Erich H Active and passive immunization against pharmacologically active hapten molecules using a synthetic carrier compound composed of similar elements
US20060154259A1 (en) * 2005-01-07 2006-07-13 Huan-Cheng Chang Diamond crystallites for biotechnological applications
RU2408368C2 (ru) 2005-06-27 2011-01-10 Биовэйл Лэборэториз Интернэшнл С.Р.Л. Препараты соли бупропиона с модифицированным высвобождением
US20070020620A1 (en) * 2005-07-14 2007-01-25 Finn M G Compositions and methods for coupling a plurality of compounds to a scaffold
US20110086086A1 (en) * 2005-07-26 2011-04-14 Pfizer Inc Transdermal system for varenicline
US20110027220A1 (en) * 2005-09-28 2011-02-03 Cytos Biotechnology Ag Interleukin-1 Conjugates and Uses Thereof
WO2007070682A2 (fr) 2005-12-15 2007-06-21 Massachusetts Institute Of Technology Systeme de criblage de particules
CA2646942C (fr) 2006-03-16 2014-07-29 Modoral Brands Inc. Composition amelioree de tabac a priser
CA2648099C (fr) 2006-03-31 2012-05-29 The Brigham And Women's Hospital, Inc Systeme pour l'administration ciblee d'agents therapeutiques
US20080044462A1 (en) * 2006-04-06 2008-02-21 Collegium Pharmaceutical, Inc. Delaware Stabilized transdermal bupropion preparations
EP1849780A1 (fr) 2006-04-21 2007-10-31 De Staat der Nederlanden, vert. door de minister van VWS Vaccin contre la toxicomanie de nicotine
EP1854478A1 (fr) * 2006-05-12 2007-11-14 Cytos Biotechnology AG Composition vaccinale comprenant des conjugués nicotine-porteur
EP2019691B1 (fr) 2006-05-15 2020-08-12 Massachusetts Institute of Technology Polymères pour particules fonctionnelles
WO2007137117A2 (fr) * 2006-05-17 2007-11-29 Massachusetts Institute Of Technology Administration de médicaments dirigée par aptamères
US9381477B2 (en) 2006-06-23 2016-07-05 Massachusetts Institute Of Technology Microfluidic synthesis of organic nanoparticles
US20100144845A1 (en) * 2006-08-04 2010-06-10 Massachusetts Institute Of Technology Oligonucleotide systems for targeted intracellular delivery
US20080087279A1 (en) * 2006-10-11 2008-04-17 Tieck Catharine Laureen Johnso Metered dose inhaler
EP2086977A2 (fr) * 2006-11-09 2009-08-12 Pfizer Products Inc. Polymorphes d'intermédiaires nicotiniques
WO2008079324A1 (fr) * 2006-12-21 2008-07-03 Boston Biomedical Research Institute Modulation immunologique du facteur de croissance 1 de type insuline destinée à la prévention/traitement du cancer et à prolonger la durée de vie
EP2134830A2 (fr) 2007-02-09 2009-12-23 Massachusetts Institute of Technology Bioréacteur oscillant pour la culture de cellules
WO2008124632A1 (fr) 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Nanoparticules assistées par des composés amphiphiles pour délivrance ciblée
WO2008124634A1 (fr) * 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Micelles inverses encapsulées par un polymère
EP1982729A1 (fr) * 2007-04-20 2008-10-22 Cytos Biotechnology AG Régime de vaccination pour les vaccins des cellules B
WO2008147526A1 (fr) * 2007-05-23 2008-12-04 The Trustees Of The University Of Pennsylvania Véhicules ciblés pour la délivrance intracellulaire de médicaments
CA2917512C (fr) 2007-10-12 2025-08-05 President And Fellows Of Harvard College Nanotechnologie des vaccins
WO2009070533A1 (fr) * 2007-11-29 2009-06-04 Complegen, Inc. Procédés d'inhibition de stéaroyle-coa désaturase
US8710069B2 (en) * 2008-03-27 2014-04-29 University Of Kentucky Research Foundation Opioid-nornicotine codrugs combinations for pain management
US20090270264A1 (en) * 2008-04-09 2009-10-29 United States Army As Represenfed By The Secretary Of The Army, On Behalf Of Usacidc System and method for the deconvolution of mixed dna profiles using a proportionately shared allele approach
US20110086063A1 (en) * 2008-06-04 2011-04-14 Cornell University Vaccines for prevention and treatment of addiction
US20110182918A1 (en) 2008-06-13 2011-07-28 Nabi Biopharmaceuticals Personalized drug treatment and smoking cessation kit and method
US20100009389A1 (en) * 2008-07-14 2010-01-14 Masood Unnabi Khan Method of Making and Using Versatile Positive Controls and Antibody Detection Assays
PL2313390T3 (pl) * 2008-08-08 2013-03-29 Novartis Ag Proces otrzymywania haptenów na bazie nikotyny
WO2010042743A2 (fr) * 2008-10-08 2010-04-15 Chimeros Inc. Multiplexes chimères, compositions et procédés permettant de les utiliser
US8343497B2 (en) * 2008-10-12 2013-01-01 The Brigham And Women's Hospital, Inc. Targeting of antigen presenting cells with immunonanotherapeutics
US8591905B2 (en) * 2008-10-12 2013-11-26 The Brigham And Women's Hospital, Inc. Nicotine immunonanotherapeutics
US8277812B2 (en) 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
US8343498B2 (en) 2008-10-12 2013-01-01 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
CN101413946B (zh) * 2008-10-31 2012-08-08 江南大学 一种盐酸西布曲明的酶联免疫检测方法
US8151804B2 (en) * 2008-12-23 2012-04-10 Williams Jonnie R Tobacco curing method
PL222496B1 (pl) * 2009-04-10 2016-08-31 Inst Biochemii I Biofizyki Pan Wektorowa cząsteczka wirusopodobna, sposób jej wytwarzania oraz kompozycja farmaceutyczna zawierająca wektorową cząsteczkę wirusopodobną
KR20120022984A (ko) * 2009-04-21 2012-03-12 셀렉타 바이오사이언시즈, 인크. Ｔｈ１ 편향 반응을 제공하는 면역나노치료법
WO2010138192A2 (fr) 2009-05-27 2010-12-02 Selecta Biosciences, Inc. Nanotransporteurs dont les composants présentent des vitesses de libération différentes
WO2011014679A1 (fr) 2009-07-31 2011-02-03 Nabi Biopharmaceuticals Procédé et trousse pour traiter la dépendance à la nicotine
US9125907B2 (en) * 2009-09-30 2015-09-08 Christopher Shaari Use of botulinum neurotoxin to treat substance addictions
WO2011050158A1 (fr) 2009-10-22 2011-04-28 The Trustees Of Columbia University In The City Of New York Vaccins anti-drogue
EP2547362B1 (fr) * 2010-03-17 2021-08-25 Cornell University Vaccin adénoviral dissocié contre les drogues toxicomanogènes
WO2011120994A1 (fr) 2010-03-29 2011-10-06 Inserm (Institut National De La Sante Et De La Recherche Medicale) Compositions pharmaceutiques comprenant un polypeptide comprenant au moins un motif cxxc et des antigènes hétérologues et leurs utilisations
GB201006324D0 (en) 2010-04-15 2010-06-02 Glaxosmithkline Biolog Sa Vaccine
CN102905728B (zh) 2010-05-26 2015-11-25 西莱克塔生物科技公司 具有不偶合的佐剂的纳米载体组合物
WO2012031220A2 (fr) 2010-09-03 2012-03-08 University Of Florida Research Foundation, Inc. Composés de nicotine et leurs analogues, procédés de synthèse pour fabriquer les composés et procédés d'utilisation
US20120328605A1 (en) * 2010-10-27 2012-12-27 Daniel Larocque Compositions and uses
EP2640190A4 (fr) 2010-11-05 2016-05-11 Selecta Biosciences Inc Composés nicotiniques modifiés et procédés associés
MX356426B (es) 2011-04-04 2018-05-29 Univ Iowa Res Found Metodos para mejorar inmunogenicidad de vacuna.
TWI488865B (zh) * 2011-06-16 2015-06-21 Nat Univ Chung Hsing 經改造之油體鈣蛋白（ｃａｌｅｏｓｉｎｓ）及其用於半抗原之抗體製造
US20130028857A1 (en) 2011-07-29 2013-01-31 Selecta Biosciences, Inc. Synthetic nanocarriers comprising polymers comprising multiple immunomodulatory agents
WO2013068949A1 (fr) * 2011-11-07 2013-05-16 Novartis Ag Molécule porteuse comprenant un antigène spr0096 et un antigène spr2021
CA2860310C (fr) * 2011-12-21 2023-03-21 Apse, Llc Procedes d'utilisation de vlp avec des capsides resistants aux hydrolases
CN104011080B (zh) 2011-12-22 2017-10-20 弗·哈夫曼-拉罗切有限公司 用于真核细胞的全长抗体展示系统及其用途
US10093947B2 (en) 2012-02-28 2018-10-09 Cornell University AAV-directed persistent expression of an anti-nicotine antibody gene for smoking cessation
US10004811B2 (en) 2012-04-13 2018-06-26 Cornell University Development of a highly efficient second generation nicotine-conjugate vaccine to treat nicotine addiction
BR112014032916A2 (pt) * 2012-06-28 2017-08-01 Pfizer anticorpos anti-fármacos e usos destes para o monitoramento de fármaco
BR112014029403A2 (pt) 2012-07-04 2018-10-09 F. Hoffmann-La Roche Ag conjugados, anticorpo e formulação farmacêutica
US9457096B2 (en) 2012-07-06 2016-10-04 Consejo Nacional De Investigaciones Cientificas Y Tecnicas (Concet) Protozoan variant-specific surface proteins (VSP) as carriers for oral drug delivery
US20160051693A1 (en) 2013-03-21 2016-02-25 Genisphere, Llc Cellular Delivery of DNA Intercalating Agents
BR112015029559A2 (pt) 2013-06-19 2017-12-12 Apse Llc partícula similar a vírus, ácido nucleico e métodos para produzir rna de fita dupla e sirna, shrna, sshrna, 1shrna e mirna
EP3041478A4 (fr) * 2013-09-05 2017-04-26 Immune Design Corp. Compositions de vaccin pour toxicomanie
EP3089759B1 (fr) 2014-01-03 2018-12-05 F. Hoffmann-La Roche AG Conjugués covalents entre un anticorps et une toxine polypeptidique
EP3089758B1 (fr) 2014-01-03 2021-01-27 F.Hoffmann-La Roche Ag Conjugués d'anticorps helicar-anti-helicar liés par covalence et leurs utilisations
ES2895752T3 (es) 2014-01-03 2022-02-22 Hoffmann La Roche Anticuerpos biespecíficos anti-hapteno/anti-receptor de la barrera hematoencefálica, complejos de los mismos y su uso como lanzaderas a través de la barrera hematoencefálica
CN107567497A (zh) 2015-04-17 2018-01-09 库瑞瓦格股份公司 Rna的冻干
US9855317B2 (en) 2015-04-27 2018-01-02 Reflex Medical, Inc. Systems and methods for sympathetic cardiopulmonary neuromodulation
WO2016184576A2 (fr) 2015-05-20 2016-11-24 Curevac Ag Composition de poudre sèche comprenant de l'arn à chaîne longue
SG10201910431RA (en) 2015-05-20 2020-01-30 Curevac Ag Dry powder composition comprising long-chain rna
CN104897864B (zh) * 2015-06-18 2016-08-31 北京勤邦生物技术有限公司 检测金刚烷胺的酶联免疫试剂盒及其应用
CN108884127A (zh) * 2016-01-21 2018-11-23 斯克利普斯研究院 合成的阿片类疫苗
US11246879B2 (en) 2016-02-09 2022-02-15 Tulai Therapeutics, Inc. Methods, agents, and devices for local neuromodulation of autonomic nerves
IL260983B (en) 2016-02-19 2022-07-01 Genisphere Llc Nucleic acid carriers and methods of medical use
CA3031761A1 (fr) 2016-06-29 2018-01-04 Tulavi Therapeutics, Inc. Traitement de la septicemie et des etats inflammatoires associes par neuromodulation locale du systeme nerveux autonome
US11602559B2 (en) * 2016-10-03 2023-03-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services HIV-1 Env fusion peptide immunogens and their use
CN106905434B (zh) * 2017-02-28 2021-01-26 国药中生生物技术研究院有限公司 一种包含蹄蝠肝炎病毒核心蛋白的重组融合蛋白及其制备方法和应用
CN107501409A (zh) * 2017-09-06 2017-12-22 杨蕾 一种尿酸人工抗原的制备方法
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
CN107982517B (zh) * 2017-12-15 2020-03-06 苏州科技城医院 治疗心肌缺血型慢性心力衰竭的西药复方组合物
US20210315587A1 (en) 2018-07-02 2021-10-14 Tulavi Therapeutics, Inc. Methods and devices for in situ formed nerve cap with rapid release
AU2019299519B2 (en) 2018-07-02 2025-03-06 Incept Llc Methods and devices for in situ formed nerve cap
CN109884021A (zh) * 2019-03-29 2019-06-14 铁道警察学院 一种量子点标记的thc包被抗原、其制备方法及利用其检测食品中大麻含量的方法
JP2022529781A (ja) 2019-04-17 2022-06-24 コンパス パスファインダー リミテッド サイロシビンによるうつ病及び他の様々な障害の治療
US20230063876A1 (en) * 2020-03-02 2023-03-02 Unm Rainforest Innovations Virus-Like Particle Vaccines for Opioid Drugs
CN111363011B (zh) * 2020-03-13 2021-08-24 北京大学 一种甲基苯丙胺疫苗及其制备方法与应用
WO2021215952A1 (fr) 2020-04-24 2021-10-28 Общество С Ограниченной Ответственностью "Индженик" Procédé de production de particules de bactériophages de la famille levivirus
US12240813B2 (en) 2020-05-19 2025-03-04 Cybin Irl Limited Deuterated tryptamine derivatives and methods of use
EP4157348A4 (fr) * 2020-05-27 2024-06-19 Behnam, Babak Compositions et méthodes permettant de traiter une dépendance à la morphine, à l'héroïne et à l'alcool
CN112924665B (zh) * 2021-02-19 2023-10-03 山东莱博生物科技有限公司 一种抗体辣根过氧化物酶标记物及其制备与应用
CN114344288B (zh) * 2022-01-25 2023-07-04 深圳技术大学 盐酸多塞平在制备抗病毒药物中的应用
CN114907255A (zh) * 2022-04-25 2022-08-16 杭州同舟生物技术有限公司 一种利他林人工半抗原、人工抗原及其制备方法和应用
CN116283885B (zh) * 2022-12-01 2025-02-14 杭州奥泰生物技术股份有限公司 一种帕罗西汀半抗原和人工抗原及其制备方法与应用
WO2025111546A1 (fr) * 2023-11-22 2025-05-30 Board Of Trustees Of Michigan State University Développement de vaccins anti-opioïdes à large spectre
CN122011194A (zh) * 2025-12-04 2026-05-12 中南大学 一种阿米替林抗体、试剂盒

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US64529A (en) * 1867-05-07 hellen
US175711A (en) * 1876-04-04 Improvement in bale-ties
US157479A (en) * 1874-12-08 Improvement in fire-proof shutters
US81295A (en) * 1868-08-18 bob in son
US175290A (en) * 1876-03-28 Improvement in rotary postmarking and canceling presses
US64533A (en) * 1867-05-07 William s
US388866A (en) 1888-09-04 O o o o o o oop o o q o o q q
BE759838A (fr) 1969-12-04 1971-06-03 Wellcome Found Cetones a activite biologique
US3885046A (en) 1969-12-04 1975-05-20 Burroughs Wellcome Co Meta chloro or fluoro substituted alpha-T-butylaminopropionphenones in the treatment of depression
US4045420A (en) 1973-05-29 1977-08-30 Syva Company Non-oxo-carbonyl containing benzoyl ecgonine and cocaine compounds polypeptide and derivatives thereof
US3888866A (en) 1973-06-01 1975-06-10 Syva Co Nitrogen derivatives of benzoyl ecgonine
US4197237A (en) 1973-06-01 1980-04-08 Syva Company Antibodies to nitrogen derivatives of benzoyl ecgonine antigenic conjugates thereof
US4722840A (en) 1984-09-12 1988-02-02 Chiron Corporation Hybrid particle immunogens
CA1319101C (fr) 1986-09-03 1993-06-15 Marta Iris Sabara Proteine de capside nucleique de rotavirus avec ou sans peptides liants comme porteurs de macromolecules immunologiques
US5374426A (en) 1986-09-03 1994-12-20 University Of Saskatchewan Rotavirus nucleocapsid protein VP6 in vaccine compositions
WO1988001873A1 (fr) 1986-09-22 1988-03-24 Emory University Vaccin et procede de preparation
US5143726A (en) 1986-12-09 1992-09-01 The Scripps Research Institute T cell epitopes of the hepatitis B virus nucleocapsid protein
US4918166A (en) 1987-04-10 1990-04-17 Oxford Gene Systems Limited Particulate hybrid HIV antigens
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4788189A (en) 1988-02-29 1988-11-29 Glazer Howard I Method to treat smoking withdrawal symptoms by potentiated central noradrenergic blocking
JPH0656106B2 (ja) 1988-10-29 1994-07-27 マツダ株式会社 過給機付エンジンの吸気装置
CA2005726A1 (fr) * 1988-12-21 1990-06-21 Haruo Tomita Composition a base de resine thermoplastique
GB8903313D0 (en) 1989-02-14 1989-04-05 Wellcome Found Conjugates
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
ATE121754T1 (de) 1989-09-04 1995-05-15 Wellcome Found Vakzine gegen bordetella.
ES2284161T3 (es) 1990-01-12 2007-11-01 Amgen Fremont Inc. Generacion de anticuerpos xenogenicos.
GB9001694D0 (en) 1990-01-25 1990-03-28 Therapeutic Antibodies Inc Immunogenic compositions
US5178882A (en) 1990-06-22 1993-01-12 The Regents Of The University Of California Viral decoy vaccine
US5334394A (en) 1990-06-22 1994-08-02 The Regents Of The University Of California Human immunodeficiency virus decoy
CH678394A5 (fr) 1990-08-22 1991-09-13 Cerny Erich H
US6699474B1 (en) * 1990-08-20 2004-03-02 Erich Hugo Cerny Vaccine and immunserum against drugs of abuse
SE9003978D0 (sv) 1990-12-13 1990-12-13 Henrik Garoff Dna expressionssystem baserade paa ett virus replikon
WO1992011291A1 (fr) 1990-12-20 1992-07-09 Smithkline Beecham Biologicals (S.A.) VACCINS A BASE DE l'ANTIGENE D'ENVELOPPE DU VIRUS DE L'HEPATITE B
GB9101550D0 (en) 1991-01-24 1991-03-06 Mastico Robert A Antigen-presenting chimaeric protein
WO1992021333A2 (fr) 1991-05-24 1992-12-10 Pharmavene, Inc. Traitement des symptomes de sevrage et de manque dus a des drogues au moyen d'inhibiteurs d'oxydase de monoamine de type b
GB9114003D0 (en) 1991-06-28 1991-08-14 Mastico Robert A Chimaeric protein
US5232082A (en) * 1992-01-28 1993-08-03 Philip Morris Incorporated Pinless belt feeder
FR2713225B1 (fr) 1993-12-02 1996-03-01 Sanofi Sa N-pipéridino-3-pyrazolecarboxamide substitué.
FR2692575B1 (fr) 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
US6004763A (en) 1992-09-11 1999-12-21 Institut Pasteur Antigen-carrying microparticles and their use in the induction of humoral or cellular responses
FR2695563B1 (fr) 1992-09-11 1994-12-02 Pasteur Institut Microparticules portant des antigènes et leur utilisation pour l'induction de réponses humorales ou cellulaires.
JPH08505625A (ja) 1993-01-11 1996-06-18 ダナ−ファーバー キャンサー インスティチュート 細胞毒性ｔリンパ球応答の誘導
US6210677B1 (en) * 1993-01-29 2001-04-03 Robert C. Bohannon Method to reduce the physiologic effects of drugs on mammals
AU6172194A (en) 1993-02-08 1994-08-29 Paravax, Inc. Defective sindbis virus vectors that express (toxoplasma gondii) p30 antigens
US5506268A (en) 1993-06-11 1996-04-09 Nps Pharmaceuticals, Inc. Use of isovaleramide as a mild anxiolytic and sedative agent
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
US5596106A (en) 1994-07-15 1997-01-21 Eli Lilly And Company Cannabinoid receptor antagonists
AT402898B (de) 1994-08-08 1997-09-25 Int Centre Genetic Eng & Bio Molekulares präsentiersystem
US5876727A (en) 1995-03-31 1999-03-02 Immulogic Pharmaceutical Corporation Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
WO1996030523A2 (fr) 1995-03-31 1996-10-03 Hans Wolf Systeme de presentation d'antigenes fonde sur des particules similaires a des retrovirus
ATE254930T1 (de) * 1995-03-31 2003-12-15 Xenova Res Ltd Hapten-träger-konjugate zur anwendung in der drogen-missbrauchs-therapie
US5792462A (en) 1995-05-23 1998-08-11 University Of North Carolina At Chapel Hill Alphavirus RNA replicon systems
CA2245497C (fr) 1996-03-01 2009-02-24 Novartis Ag Immunogenes peptidiques utilises comme vaccins et agents therapeutiques contre les allergies
JPH11505547A (ja) 1996-03-13 1999-05-21 エール ユニバーシティ ナルトレキソン及び関連化合物を用いる禁煙処置
US5770380A (en) 1996-09-13 1998-06-23 University Of Pittsburgh Synthetic antibody mimics--multiple peptide loops attached to a molecular scaffold
GB9621091D0 (en) 1996-10-09 1996-11-27 Fondation Pour Le Perfectionem Attenuated microorganisms strains and their uses
WO1999007839A2 (fr) 1997-08-05 1999-02-18 Vlaams Interuniversitair Instituut Voor Biotechnologie Nouvel antigene immunoprotecteur contre la grippe a et son utilisation dans la vaccination
US6169175B1 (en) 1997-08-06 2001-01-02 Centers For Disease Control And Prevention Preparation and use of recombinant influenza A virus M2 construct vaccines
US6054312A (en) 1997-08-29 2000-04-25 Selective Genetics, Inc. Receptor-mediated gene delivery using bacteriophage vectors
ATE232384T1 (de) 1997-10-03 2003-02-15 Cary Medical Corp Zusammensetzungen zur behandlung von nikotinabhängigkeit, enthaltend mecamylamin und bupropion
US6605610B1 (en) 1997-12-31 2003-08-12 Pfizer Inc Aryl fused azapolycyclic compounds
ATE249240T1 (de) 1998-02-12 2003-09-15 Immune Complex Corp Strategisch modifizierte hepatitis b kernproteine und ihre derivate
US5990085A (en) 1998-05-04 1999-11-23 Michigan State University Inhibin-HBc fusion protein
SE9801923D0 (sv) * 1998-05-29 1998-05-29 Independent Pharmaceutical Ab Nicotine vaccine
TWI227241B (en) 1998-06-20 2005-02-01 United Biomedical Inc IgE-CH3 domain antigen peptide, peptide conjugate containing the same, and pharmaceutical composition for treating allergies containing the peptide conjugate
US6231964B1 (en) * 1998-06-30 2001-05-15 Ncr Corporation Thermal transfer ribbons with large size wax or resin particles
US7157092B1 (en) 1998-06-30 2007-01-02 Om Pharma Acyl pseudodipeptides, preparation method and pharmaceutical compositions containing same
ATE314095T1 (de) 1998-10-21 2006-01-15 Us Health Virusähnliche partikel zur induktion von autoantikörpern
US6380364B1 (en) 1998-11-23 2002-04-30 Loyola University Of Chicago Chimeric biotin-binding papillomavirus protein
PL192016B1 (pl) 1998-11-30 2006-08-31 Cytos Biotechnology Ag Kompozycja, sposób wytwarzania sztucznego, uporządkowanego i powtarzalnego układu antygenu, zastosowanie kompozycji oraz kompozycja szczepionki
US6232082B1 (en) 1998-12-01 2001-05-15 Nabi Hapten-carrier conjugates for treating and preventing nicotine addiction
KR100715954B1 (ko) 1998-12-04 2007-05-09 바이오겐 아이덱 엠에이 인코포레이티드 펩티드 리간드에 의하여 부착된 다중 면역원성 성분을보유한 ｈｂｖ 코어 항원 입자
WO2000050461A1 (fr) 1999-02-25 2000-08-31 Smithkline Beecham Biologicals S.A. Epitopes ou mimotopes derives des domaines c-epsilon-3 ou c-epsilon-4 des ige, leurs antagonistes et leur utilisation therapeutique
FR2790474B1 (fr) 1999-03-05 2001-04-06 Synthelabo Derives de pyridopyranoazepines, leur preparation et leur application en therapeutique
CA2365970A1 (fr) 1999-04-07 2000-10-12 Thomas Jefferson University Peptides synthetiques issus de chimiokines
EP1078632A1 (fr) 1999-08-16 2001-02-28 Sanofi-Synthelabo Utilisation des inhibiteurs de monoamine oxydases dans la fabrication d'un médicament contre l'obésité
US20030086938A1 (en) 2000-02-21 2003-05-08 Jensen Martin Roland Novel methods for down-regulation of amyloid
WO2001077158A1 (fr) 2000-04-07 2001-10-18 University Of Leeds Innovations Limited Proteines hybrides de l'antigene capsidique de l'hepatite b
WO2001085208A2 (fr) * 2000-05-05 2001-11-15 Cytos Biotechnology Ag Jeu ordonne d'antigenes moleculaires
EP1294893B1 (fr) 2000-06-22 2006-03-15 UCB Pharma Limited Modification de l'antigene capsidique de l'hepatite b
US20030138769A1 (en) 2000-08-16 2003-07-24 Birkett Ashley J. Immunogenic HBc chimer particles having enhanced stability
US7320793B2 (en) 2001-01-19 2008-01-22 Cytos Biotechnology Ag Molecular antigen array
US7128911B2 (en) 2001-01-19 2006-10-31 Cytos Biotechnology Ag Antigen arrays for treatment of bone disease
US7094409B2 (en) 2001-01-19 2006-08-22 Cytos Biotechnology Ag Antigen arrays for treatment of allergic eosinophilic diseases
AU2002251821A1 (en) 2001-01-26 2002-08-06 The Scripps Research Institute Nicotine immunogens and antibodies and uses thereof
US7115266B2 (en) 2001-10-05 2006-10-03 Cytos Biotechnology Ag Angiotensin peptide-carrier conjugates and uses thereof
FR2831883B1 (fr) 2001-11-08 2004-07-23 Sanofi Synthelabo Forme polymorphe du rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
RU2197268C1 (ru) * 2001-12-07 2003-01-27 Эпштейн Олег Ильич Лекарственное средство и способ лечения никотинизма
US20030219459A1 (en) 2002-01-18 2003-11-27 Cytos Biotechnology Ag Prion protein carrier-conjugates
CA2477268A1 (fr) * 2002-03-01 2003-10-09 The Board Of Regents Of The University Of Nebraska Compositions et composes destines a un vaccin contre la nicotine et utilisant un agoniste selectif de reponse d'un recepteur de cellule presentatrice d'antigene comme adjuvant moleculaire
JP4726483B2 (ja) * 2002-07-17 2011-07-20 サイトス バイオテクノロジー アーゲー 分子抗原アレイ
KR101228376B1 (ko) * 2002-07-18 2013-01-31 사이토스 바이오테크놀로지 아게 합텐-캐리어 컨쥬게이트 및 그의 용도
DE60336902D1 (de) 2002-07-19 2011-06-09 Cytos Biotechnology Ag Impfstoffzusammensetzungen enthaltende amyloid beta 1-6 antigenarrays
MXPA04011247A (es) 2002-07-19 2005-02-17 Cytos Biotechnology Ag Conjugados portadores de grelina.

Also Published As

Publication number Publication date
AU2003250106B2 (en) 2009-11-26
EP2392345A2 (fr) 2011-12-07
MXPA04012010A (es) 2005-03-07
NZ537003A (en) 2008-03-28
JP5084103B2 (ja) 2012-11-28
EP1523334A2 (fr) 2005-04-20
CN101574518B (zh) 2012-08-22
CN100518823C (zh) 2009-07-29
IL165249A0 (en) 2005-12-18
US7452541B2 (en) 2008-11-18
KR20050027169A (ko) 2005-03-17
AU2003250106A1 (en) 2004-02-09
US6932971B2 (en) 2005-08-23
RU2008101922A (ru) 2009-07-27
ZA200409389B (en) 2007-01-31
KR101228376B1 (ko) 2013-01-31
US20050281845A1 (en) 2005-12-22
US20130142821A1 (en) 2013-06-06
WO2004009116A3 (fr) 2004-03-18
CN101574518A (zh) 2009-11-11
US20040059094A1 (en) 2004-03-25
KR20120041739A (ko) 2012-05-02
US20100129395A1 (en) 2010-05-27
PL375598A1 (en) 2005-12-12
RU2005104430A (ru) 2005-08-10
BR0312297A (pt) 2005-04-12
CN1668331A (zh) 2005-09-14
CA2487849A1 (fr) 2004-01-29
EP2392345A3 (fr) 2012-03-07
WO2004009116A2 (fr) 2004-01-29
JP2006504654A (ja) 2006-02-09
US8187607B2 (en) 2012-05-29
RU2326693C2 (ru) 2008-06-20

Similar Documents

Publication Publication Date Title
WO2004009116A3 (fr) Conjugues haptene-porteur et utilisations de ceux-ci
BR9711580A (pt) Conjugados hapteno-veìculo para uso em terapia contra uso indiscriminado de drogas e métodos para preparação destes
IL267381A (en) A pharmaceutical preparation containing dextromethorphan and quinidine for the treatment of nervous disorders
EP1594542A4 (fr) Conjugues de medicaments anticorps anti-cd70, utilisation desdits conjugues dans le traitement du cancer et des troubles immunitaires
WO2005097211A3 (fr) Compositions adjuvantes ameliorant la reponse immunitaire a des vaccins et methodes d'utilisation
MXPA01005511A (es) Conjugados de hapteno-portador para tratar y prevenir la adiccion a la nicotina.
CY1106602T1 (el) Παραγωγα αδαμαντανιου για τη θεραπεια φλεγμονωδων, ανοσολογικων και καρδιαγγειακων ασθενειων
HUP0400231A3 (en) Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer
IL138424A0 (en) Covalently reactive antigen analogs and pharmaceutical compositions containing the same
DE60234183D1 (de) Verwendung von methylnaltrexon zur behandlung von immunsuppression
EP1782837A3 (fr) Conjugués comprenant un haptène et un vecteur utilisés dans la thérapie des abus de drogues (nicotine)
DK0814843T3 (da) Haptenbærerkonjugater til anvendelse i behandling af stofmisbrug
ATE355288T1 (de) Verbindungen und therapeutische methoden
EP2298811A3 (fr) Anticorps humains à neutralisation anti-ifn-gamma en tant que qu'inhibiteurs sélectifs de chemin ifn-gamma
DE59107814D1 (de) Impfstoff gegen drogen
MXPA05013200A (es) Derivados de estaurosporina para sindrome hipereosinofilico.
NO20043707L (no) Nye immuno effektor forbindelser
ATE325803T1 (de) Glycokonjugate, glycoaminosäure, deren zwischenprodukte, und ihre verwendung
WO2004029214A3 (fr) Anticorps lies a la sous-unite alpha de lfa-1 et methodes d'utilisation
EP0955366A4 (fr) Proteine antigenique provenant de la malassezia
ATE310750T1 (de) Verotoxin b untereinheit zur immunisierunug
SG156658A1 (en) Treatment of diseases
TW200500073A (en) Pharmaceutical composition comprising an indolopyrrolocarbazole derivative and use thereof
IL160412A0 (en) Methods and pharmaceutical compositions for immune deception, particularly in the treatment of cancer